Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity

9th November 2016

Oxford Cancer Biomarkers, spun out from Oxford University in 2011 to develop tests for personalised medicine in cancer patients, has enrolled its first patient in a clinical study.

The first colorectal cancer patient has been enrolled in the PRECISE trial featuring the ColoTox Assay.

The PRECISE trial; ‘Predicting, Recording and rEducing Chemotherapy Induced Side Effects’: a pilot feasibility study of a
new germline genetic test for the risk of toxicity with fluoropyrimidine-based chemotherapy. The ColoTox assay
improves the patient pathway in the treatment of colorectal cancer, by improving safety.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways
and plans to develop similar tests for other cancer indications. The ColoTox test assesses the likelihood that the patient
will suffer from life threatening toxicity, permitting the clinical team to make a priori dose reduction and lessen the
chance of serious side effects and even chemotherapy induced death. Colorectal cancer is the fourth most common
cancer in the UK behind breast, lung and prostate cancer.

Over 40,000 new cases are diagnosed in the UK every yearand over 15,000 prove fatal.

Further details can be found at http://www.oxfordbio.com/news/

Press release sign up